Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.
May 3, 2022
In 2005, Pfizer launched a Phase 1 trial for the kinase inhibitor crizotinib. Six years later, it was approved, thanks...
Read article
February 26, 2021
Empowering Statisticians to Create Complex Bayesian Clinical Study Designs
In the world of clinical trials, the pace of innovation is accelerating, and approaches such as Bayesian methods are...
Read article
October 27, 2020
Bayesian Dose-Finding Designs – An Overview
Cytel recently conducted a webinar on Bayesian Dose-finding Designs for Modern Drug Development, presented by Dr. Yuan...
Read article
October 23, 2020
Yuan Ji on U-Design: An All New Efficacy and Toxicity Dose-Finding Module
Cytel’s New Horizons Webinar Series introduces you to the latest innovations in statistical trial design. This webinar...
Read article
September 28, 2020
Advantages of platform designs for investigating COVID-19 therapies
Cytel has recently designed and implemented the TOGETHER Trials, funded by the Bill & Melinda Gates Foundation to...
Read article
September 17, 2020
East Alloy: Accelerating the pace of innovation
Keeping up with the rapid pace of clinical development means that we need to adopt the innovative or computationally...
Read article
August 31, 2020
Adopt innovative and computationally intensive designs with East Alloy
Pantelis Vlachos, Principal, Strategic Consultant at Cytel, conducted a webinar to introduce the capabilities of East...
Read article
August 19, 2020
Webinar on Adaptive Designs for Dose Finding: Part 2
Bjoern Bornkamp, Statistical Methodologist at Novartis and Jose Pinheiro, Senior Director, Johnson & Johnson provided...
Read article
August 13, 2020
Webinar: Adaptive Designs for Dose Finding
Bjoern Bornkamp, Statistical Methodologist at Novartis and Jose Pinheiro, Senior Director, Johnson & Johnson provided...
Read article
July 22, 2020
Access Sustainable, Verified Innovation with East Alloy
Cytel brings to you a new blog series on technology and Bayesian decision-making by Pantelis Vlachos,...
Read article
June 9, 2020
Melinda Gates, on COVID-19 and Drug Development in Emerging Economies
Trevor Mundel leads the Bill & Melinda Gates Foundation’s efforts to develop high-impact interventions against the...
Read article
February 9, 2017
Inside an Oncology Statistician's Toolkit
In this blog, Adam Hamm, PhD, Director Biostatistics at Cytel shares some of the most important knowledge he uses in...
Read article
January 30, 2017
Accelerating development with combined SAD/MAD approach
Single ascending dose (SAD) and multiple ascending dose (MAD) studies are typically the first in human studies. They...
Read article
August 23, 2016
How does the T-Statistic stack up for finding MTD?
At the recent JSM meeting in Chicago, Cytel's Jim Bolognese presented the results of work he has conducted evaluating...
Read article
July 5, 2016
PROC MCPMod in Bronchodilator Case Study
At a recent PhUSE SDE, Cytel’s Chitra Tirodkar presented how East PROC MCPMod could be used to help solve the problem...
Read article
August 10, 2015
Mitigate Phase 3 Clinical Trial Risk by Optimizing Phase 2 Data
When approaching a Phase 3 clinical trial, the need to ‘de-risk’ the massive investment often leads sponsors on a quest...
Read article
April 16, 2015
Phase 2 Designs for Clinical Utility Limiting Therapies
When testing certain types of new drugs it is known in advance that the adverse side-effects of the medication will...
Read article
January 22, 2015
Adaptive Clinical Trial Strategies for the Limited Early Phase Budget
The Journal of the American Medical Association recently published an article entitled ‘The Anatomy of Medical...
Read article
December 9, 2014
Drug Supply Planning for Dose-Ranging Adaptive Trials
When planning a conventional trial, one can anticipate the drug supply necessary for the trial by determining how the...
Read article
December 4, 2014
Operationally Seamless & Inferentially Seamless Adaptive Designs
Fulyzaq® from Napo/Salix was the first drug ever to be approved using an adaptive two-stage "seamless" clinical trial...
Read article
November 12, 2014
Ranking Adaptive Dose-Finding Designs using Clinical Utility Functions
Clinical utility functions provide Phase 2 trial sponsors with an intuitive metric by which to measure the quality of a...
Read article